Cited by 796Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Corsini, Alberto, Bellosta, Stefano, Baetta, Roberta, Fumagalli, Remo, Paoletti, Rodolfo, Bernini, Franco·1999·Pharmacology & Therapeutics

DOI 10.1016/s0163-7258(99)00045-5

Open this paper in CoChat — free account

Abstract

The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy.

Integrity signals

Registry

Crossref · 10.1016/s0163-7258(99)00045-5

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 9,216
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Coronary Plaque Disruption
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018

Show all 186 references

Research works printed but not linked: 8

Fischer, 1999, The HMG-CoA reductase inhibitor fluvastatin, Drug Metab Dispos, 27, 410
Henwood, 1995, Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia, Drugs, 31, 9
Hoffman, 1992, The interaction of lovastatin and warfarin, Conn Med, 56, 107
Mai, 1997, Clinical pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporin A (CSA), Eur J Clin Pharmacol, 52, A137
Raiteri, 1997, Pharmacological control of the mevalonate pathway, J Pharmacol Exp Ther, 281, 1144
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383
Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat, J Pharmacol Exp Ther, 257, 1225
Soma, 1995, In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypocholesterolemic drug, Cancer Res, 55, 597

Sorted by citations

Items 101–200 of 794

Binding Thermodynamics of Statins to HMG-CoA Reductase
Carbonell, T., & Freire, E. (2005) · Biochemistry · doi:10.1021/bi050905v · Cited by 103
Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering
Baetta, R., Camera, M., Comparato, C., Altana, C., Ezekowitz, M. D., & Tremoli, E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012802.69414.a8 · Cited by 100
Self-citation
Isoprenoid metabolism and the pleiotropic effects of statins
Laufs, U., & Liao, J. K. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0008-z · Cited by 100
Safety considerations for statins
Bolego, C., Baetta, R., Bellosta, S., Corsini, A., & Paoletti, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00007 · Cited by 98
Self-citation
Local delivery of controlled-release simvastatin/PLGA/HAp microspheres enhances bone repair
Ho, M., Tai, Fu, Wang, C., & Chang (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s48694 · Cited by 97
Cytochrome P450: major player in reperfusion injury
Gottlieb, R. A. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.07.004 · Cited by 96
Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs
Masubuchi, Y., & Horie, T. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215233 · Cited by 95
Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis
Teng, M., Lin, L., Zhao, Y. J., Khoo, A. L., Davis, B. R., Yong, Q. W., Yeo, T. C., & Lim, B. P. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0290-9 · Cited by 94
Myotoxicity associated with lipid-lowering drugs
Baer, A. N., & Wortmann, R. L. (2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328010c559 · Cited by 93
Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells
Potena, L., Frascaroli, G., Grigioni, F., Lazzarotto, T., Magnani, G., Tomasi, L., Coccolo, F., Gabrielli, L., Magelli, C., Landini, M. P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000109485.79183.81 · Cited by 93
Pravastatin down-regulates inflammatory mediators in human monocytes in vitro
Grip, O., Janciauskiene, S. M., & Lindgren, S. C. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00870-0 · Cited by 89
Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury
Mason, J. C., Ahmed, Z., Mankoff, R., Lidington, E. A., Ahmad, S. R., Bhatia, V. K., Kinderlerer, A. R., RANDI, A. M., & Haskard, D. O. (2002) · Circulation Research · doi:10.1161/01.res.0000038151.57577.19 · Cited by 91
Statin myopathies: pathophysiologic and clinical perspectives.
Baker, S. K., & Tarnopolsky, M. A. (2001) · PubMed · Cited by 90
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial
Dulęba, A. J., Banaszewska, B., Spaczyński, R., & Pawelczyk, L. A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.030 · Cited by 89
Pulmonary Infections in the Elderly Lead to Impaired Neutrophil Targeting, Which Is Improved by Simvastatin
Sapey, E., Patel, J. M., Greenwood, H. L., Walton, G., Hazeldine, J., Sadhra, C., Parekh, D., Dancer, R. C. A., Nightingale, P., Lord, J. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0814oc · Cited by 88
Statin-Induced Proinflammatory Response in Mitogen-Activated Peripheral Blood Mononuclear Cells through the Activation of Caspase-1 and IL-18 Secretion in Monocytes
Coward, W. R., Marei, A. M., Yang, A., Vasa‐Nicotera, M., & Chow, S. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5284 · Cited by 88
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Prevents Endothelial NO Synthase Downregulation by Atherogenic Levels of Native LDLs
Martínez‐González, J., Raposo, B., Rodrı́guez, C., & Badimón, L. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.5.804 · Cited by 88
Modulatory effects of HMG‐CoA reductase inhibitors in diabetic microangiopathy
Danesh, F. R., & Kanwar, Y. S. (2004) · The FASEB Journal · doi:10.1096/fj.03-0839rev · Cited by 86
Pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 86
The evolving role of information technology in the drug discovery process
Augen, J. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02173-6 · Cited by 85
Cholesterol-Lowering Drugs and Incident Open-Angle Glaucoma: A Population-Based Cohort Study
Marcus, M. W., Müskens, R. P. H. M., Ramdas, W. D., Wolfs, R. C. W., de Jong, P. T. V. M., Vingerling, J. R., Albert Hofman, D., Stricker, B. H. C., & Jansonius, N. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029724 · Cited by 85
Pharmacological interactions of statins
Paoletti, R., Corsini, A., & Bellosta, S. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(02)00002-8 · Cited by 85
Self-citation
Simvastatin Inhibits IL-1β-Induced Apoptosis and Extracellular Matrix Degradation by Suppressing the NF-kB and MAPK Pathways in Nucleus Pulposus Cells
Tu, J., Li, W., Zhang, Y., Wu, X., Song, Y., Kang, L., Liu, W., Wang, K., Li, S., Hua, W., et al. (2017) · Inflammation · doi:10.1007/s10753-017-0516-6 · Cited by 84
An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads
Sezaki, H., Suzuki, F., Akuta, N., Yatsuji, H., Hosaka, T., Kobayashi, M., Suzuki, Y., Arase, Y., Ikeda, K., Miyakawa, Y., et al. (2009) · Intervirology · doi:10.1159/000213504 · Cited by 82
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
Self-citation
Clinical Implications of Pharmacogenetic Variation on the Effects of Statins
Maggo, S. D. S., Kennedy, M. A., & Clark, D. W. J. (2010) · Drug Safety · doi:10.2165/11584380-000000000-00000 · Cited by 83
Drug–drug interactions that interfere with statin metabolism
Hirota, T., & Ieiri, I. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1056149 · Cited by 85
Antioxidant Properties of Carnosine Re-Evaluated with Oxidizing Systems Involving Iron and Copper Ions
Możdżan, M., Szemraj, J., Rysz, J., & Nowak, D. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_03.x · Cited by 81
Structural, Spectroscopic (NMR, IR, and Raman), and DFT Investigation of the Self-Assembled Nanostructure of Pravastatin-LDH (Layered Double Hydroxides) Systems
Cunha, V. R. R., Petersen, P. A. D., Gonçalves, M. B., Petrilli, H. M., Taviot‐Guého, C., Leroux, F., Temperini, M. L. A., & Constantino, V. R. L. (2012) · Chemistry of Materials · doi:10.1021/cm202953y · Cited by 81
Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders
Butterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80
“FPP is also the substrate for production of coenzyme Q10 (CoQ10) and dolichol [10].”
Background
Simvastatin as a Novel Strategy To Alleviate Periapical Lesions
Lin, S., Kok, S., Lee, Y., Hou, K., Lin, Y.-T., Chen, M., Wang, C.-C., & Hong, C. (2009) · Journal of Endodontics · doi:10.1016/j.joen.2009.02.004 · Cited by 80
Simvastatin induces osteogenic differentiation of murine embryonic stem cells
Pagkalos, J., Cha, J. M., Kang, Y., Heliotis, M., Tsiridis, E. E., & Mantalaris, A. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.163 · Cited by 80
Acute Myopathy in a Patient with Concomitant Use of Pravastatin and Colchicine
Alaylı, G., Cengiz, K., Cantürk, F., Durmuş, D., Akyol, Y., & Menekse, E. B. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e593 · Cited by 80
Regulation of osteoclast differentiation by statins.
Wa, G., Ap, B., Petras, S. F., Hj, H., Devalaraja, R., Renkiewicz, R. R., Baragi, Dd, T., & Vm, P. (2003) · PubMed · Cited by 80
Statins and fracture risk. A systematic review
Toh, S., & Hernández–Dı́az, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1363 · Cited by 79
Atorvastatin
Poli, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00002 · Cited by 81
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells
Izidoro‐Toledo, T. C., Guimarães, D. A., Belo, V. D. A., Gerlach, R. F., & Tanus-Santos, J. E. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0623-0 · Cited by 79
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women
Doggen, C. J. M., Lemaître, R. N., Smith, N. L., Heckbert, S. R., & Psaty, B. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00696.x · Cited by 78
Approach to the Patient Who Is Intolerant of Statin Therapy
Eckel, R. H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2689 · Cited by 78
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study
McMurtry, M. S., Bonnet, S., Michelakis, E. D., Bonnet, S. B., Haromy, A., & Archer, S. L. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00310.2006 · Cited by 78
Rosuvastatin, but not Simvastatin, Provides End-Organ Protection in Stroke-Prone Rats by Antiinflammatory Effects
Sironi, L., Gianazza, E., Gelosa, P., Guerrini, U., Nobili, E., Gianella, A., Cremonesi, B., Paoletti, R., & Tremoli, E. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000157145.98200.55 · Cited by 77
Self-citation
Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity
Seachrist, J. L., Loi, C., Evans, M. G., Criswell, K. A., & Rothwell, C. E. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi305 · Cited by 77
The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
Saravi, S. S. S., Saravi, S. S. S., Arefidoust, A., & Dehpour, A. R. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0021-5 · Cited by 77
Mutual amplification of apoptosis by statin‐induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells
Werner, M., Sacher, J., & HOHENEGGER, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705928 · Cited by 76
Statins and the autonomic nervous system
Millar, P. J., & Floras, J. S. (2013) · Clinical Science · doi:10.1042/cs20130332 · Cited by 75
Simvastatin Potently Induces Calcium-dependent Apoptosis of Human Leiomyoma Cells
Borahay, M. A., Kilic, G. S., Yallampalli, C., Snyder, R. R., Hankins, G. D. V., Al-Hendy, A. A., & Boehning, D. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.583575 · Cited by 75
ATP-dependent transport of statins by human and rat MRP2/Mrp2
Ellis, L. C. J., HAWKSWORTH, G. M., & Weaver, R. J. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.03.019 · Cited by 76
Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
Bernini, F., Poli, A., & Paoletti, R. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011908004965 · Cited by 74
Self-citation
Statin use and risk of pancreatic cancer: a meta-analysis
Cui, X., Xie, Y., Chen, M., Li, J., Liao, X., Shen, J., Shi, M., Li, W., Zheng, H., & Jiang, B. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9979-9 · Cited by 74
Statin Treatment and 3′ Polyadenylation of eNOS mRNA
Kosmidou, I., Moore, J. P., Weber, M., & Searles, C. D. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.154492 · Cited by 74
PharmGKB very important pharmacogene: SLCO1B1
Oshiro, C. M., Mangravite, L. M., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328333b99c · Cited by 72
Pitavastatin: An overview
Saito, Y. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70886-8 · Cited by 73
Pretreatment with Simvastatin Reduces Lung Injury Related to Intestinal Ischemia-Reperfusion in Rats
Pirat, A., Zeyneloğlu, P., Aldemir, D., Yücel, M., Özen, Ö., Candan, S., & Arslan, G. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000189554.41095.98 · Cited by 72
Pharmacological prevention of intimal hyperplasia: A state-of-the-art review
Melnik, T., Jordan, O., Corpataux, J.-M., Delié, F., & Saucy, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108157 · Cited by 71
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma
Schmidmaier, R., Baumann, P., Bumeder, I., Meinhardt, G., Straka, C., & Emmerich, B. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00902.x · Cited by 71
Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential
Sharma, M., & Mehta, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-52645-0 · Cited by 70
Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases
Chow, S. C. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0038-5 · Cited by 69
Simvastatin reduces MMP-3 level in interleukin 1β stimulated human chondrocyte culture
Lazzerini, P. E., Capecchi, P. L., Nerucci, F., Fioravanti, A., Chellini, F., Piccini, M., Bisogno, S., Marcolongo, R., & Pasini, F. L. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009746 · Cited by 69
Managing Statin Myopathy
Venero, C. V., & Thompson, P. D. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.002 · Cited by 68
Pharmacokinetic Interactions Between Statins and Fibrates
Corsini, A., Bellosta, S., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.007 · Cited by 69
Self-citation
Inhibition of Geranylgeranylation Mediates the Effects of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors on Microglia
Bi, X., Baudry, M., Liu, J., Yao, Y., Fu, L., Brücher, F., & LYNCH, G. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405442200 · Cited by 68
The Pleiotropic Effects of HMG-CoA Reductase Inhibitors
Waldman, A., & Kritharides, L. (2003) · Drugs · doi:10.2165/00003495-200363020-00002 · Cited by 68
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms
Bahrami, A., Bo, S., Jamialahmadi, T., & Sahebkar, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101024 · Cited by 68
Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: Standard and Fpg-modified comet assay
Gajski, G., Garaj‐Vrhovac, V., & Oreščanin, V. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.03.013 · Cited by 68
Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management
Marin, L., Colombo, P., Bebawy, M., Young, P. M., & Traini, D. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.588697 · Cited by 68
Novel genipin crosslinked atorvastatin loaded sericin nanoparticles for their enhanced antihyperlipidemic activity
Kanoujia, J., Singh, M. V., Singh, P., & Saraf, S. A. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.08.011 · Cited by 67
Effects of statins on the vasculature
Sowers, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03269-1 · Cited by 67
The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells
Rodrigues, A. C., Curi, R., Genvigir, F. D. V., Hirata, M. H., & Hirata, R. D. C. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.85 · Cited by 69
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study
Pierno, S., Didonna, M. P., Cippone, V., Luca, A. D., Pisoni, M., Frigeri, A., Nicchia, G. P., Svelto, M., Chiesa, G., Sirtori, C. R., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706917 · Cited by 67
Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma
Xu, L., Dong, X.-W., Shen, L., Li, F., Jiang, J., Cao, R., Yao, H.-Y., Shen, H., Sun, Y., & Xie, Q.-M. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.01.012 · Cited by 65
Effect of HMG-CoA Reductase Inhibitors on ??-Amyloid Peptide Levels
Höglund, K., & Blennow, K. (2007) · CNS Drugs · doi:10.2165/00023210-200721060-00002 · Cited by 63
Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
Schmitz, G., & Drobnik, W. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.088 · Cited by 64
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S. V., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-048033 · Cited by 63
Statins and skeletal muscles toxicity: From clinical trials to everyday practice
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.012 · Cited by 66
Statins: drugs for Alzheimer’s disease?
Eckert, G. P., Wood, W. G., & Müller, W. E. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0273-1 · Cited by 46
Biphasic Effect of HMG-CoA Reductase Inhibitor, Pitavastatin, on Vascular Endothelial Cells and Angiogenesis
Katsumoto, M., Shingu, T., Kuwashima, R., Nakata, A., Nomura, S., & Chayama, K. (2005) · Circulation Journal · doi:10.1253/circj.69.1547 · Cited by 63
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
Pećin, I., Hartgers, M. L., Hovingh, G. K., Dent, R. E., & Reiner, Ž. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317717346 · Cited by 64
Statins stimulate the production of a soluble form of the receptor for advanced glycation end products
Quade-Lyssy, P., Kanarek, A. M., Baiersdörfer, M., Postina, R., & Kojro, E. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038968 · Cited by 64
Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)
Sever, P. S., Poulter, N. R., Dahlöf, B., & Wedel, H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.025 · Cited by 63
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 67
Self-citation
Impact ofSLCO1B1(OATP1B1) andABCG2(BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins
Generaux, G. T., Bonomo, F., Johnson, M., & Doan, K. M. M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.562566 · Cited by 61
Rho‐GTPase and Atherosclerosis: Pleiotropic Effects of Statins
Cai, A., Zhou, Y., & Li, L. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002113 · Cited by 62
Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin
Kaneider, N. C., Reinisch, C. M., Dunzendorfer, S., Meierhofer, C., Djanani, A. M., & Wiedermann, C. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00764-4 · Cited by 61
Compactin?a review
Chakravarti, R., & Sahai, V. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1553-7 · Cited by 60
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200216421 · Cited by 60
A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells
Kopecka, J., Campia, I., Olivero, P., Pescarmona, G., Ghigo, D., Bosìa, A., & Riganti, C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.003 · Cited by 59
Protective effect of atorvastatin in cultured osteoarthritic chondrocytes
Simopoulou, T., Malizos, Κ. Ν., Poultsides, L. A., & Tsezou, A. (2009) · Journal of Orthopaedic Research® · doi:10.1002/jor.20953 · Cited by 59
Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians
Shuhaili, M. F. R. M. A., Samsudin, I. N., Stanslas, J., Hasan, S., & Thambiah, S. C. (2017) · Intern J Endocrinol Metab · doi:10.5812/ijem.43319 · Cited by 63
The Role of Statins in Vascular Disease
Laws, P. E., Spark, J. I., Cowled, P., & Fitridge, R. (2003) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2003.09.014 · Cited by 59
Controversy surrounding the safety of cerivastatin
Davidson, M. H. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.3.207 · Cited by 59
Agents and mechanisms of toxic myopathy
Kuncl, R. W. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833045a0 · Cited by 58
Statins and their influence on brain cholesterol
Cibičková, L. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.06.007 · Cited by 58
Rapid Multilabel Detection of Geranylgeranylated Proteins by Using Bioorthogonal Ligation Chemistry
Berry, A. F. H., Heal, W. P., Tarafder, A. K., Tolmachova, T., Baron, R., Seabra, M. C., & Tate, E. W. (2010) · ChemBioChem · doi:10.1002/cbic.201000087 · Cited by 58
Safety Issues with Statin Therapy
Talbert, R. L. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506778073637 · Cited by 58
Restoration of dietary-fat induced blood–brain barrier dysfunction by anti-inflammatory lipid-modulating agents
Pallebage‐Gamarallage, M. M., Lam, V., Takechi, R., Galloway, S., Clark, K., & Mamo, J. C. L. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-117 · Cited by 57
Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound
Petronio, A. S., Amoroso, G., Limbruno, U., Papini, B., Carlo, M. D., Micheli, A., Ciabatti, N., & Mariani, M. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.032 · Cited by 56
Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth
Li, H., Kuwajima, T., Oakley, D. H., Nikulina, E., Hou, J., Yang, W. S., Lowry, E. R., Lamas, N. J., Mathis, M. W., Croft, G. F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.013 · Cited by 57
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA
Passi, S., Stancato, A., Aleo, E., Dmitrieva, A., & Littarru, G. P. (2003) · BioFactors · doi:10.1002/biof.5520180213 · Cited by 57
Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance.
Chaudhry, M. Z., Wang, J. H., Blankson, S., & Redmond, H. P. (2008) · Surgical Infections · doi:10.1089/sur.2006.077 · Cited by 56
Regulation of protein prenylation
Jung, D., & Bachmann, H. S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114915 · Cited by 54

Authors: Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F.
Affiliations: University of Milan (IT)
University of Parma (IT)
Corresponding author: Corsini, Alberto
ORCID: Corsini, Alberto
Bellosta, Stefano
Baetta, Roberta
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 1999-12
Volume: 84
Issue: 3
Pages: 413-428
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/s0163-7258(99)00045-5
OpenAlex: W2045063002
Cited by: 796
References: 186
Citations by year: 2026: 5 · 2025: 6 · 2024: 27 · 2023: 19 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 14 · 2018: 21 · 2017: 30 · 2016: 30 · 2015: 27 · 2014: 35 · 2013: 31 · 2012: 38
FWCI: 5.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: statins, pharmacokinetics, pharmacodynamics, HMG-CoA reductase inhibition, mevalonate, pleiotropy, smooth muscle cell proliferation, macrophage cholesterol accumulation, atherosclerosis, drug interactions, CYP3A4, cyclosporine, rhabdomyolysis, myositis, pravastatin, fluvastatin, simvastatin, lovastatin, atorvastatin, cerivastatin
MeSH terms: Atorvastatin, Fluvastatin, Animals, Anticholesteremic Agents, Cell Division, Cytochrome P-450 Enzyme System, Drug Interactions, Fatty Acids, Monounsaturated, Heptanoic Acids, Humans, Indoles, Mevalonic Acid, Pyridines, Pyrroles, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks